Contraindicated (one)bortezomib will improve the degree or influence of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or moderate CYP2C19 inhibitors may well boost mavacamten systemic publicity, leading to coronary heart failure as a consequence of systolic dysfunction. elvitegravir/cobicistat/emtricitabine/tenofovir DF improves levels of bortezomi... https://codydwzul.blogtov.com/7230102/the-smart-trick-of-verteporfin-that-nobody-is-discussing